Search research articles
Contact Us
Filters
Showing results (61-70 of 74) with videos related to
Page
of 8
Sort By:
In Vivo (Athens, Greece)
|
September 6, 2014
EORTC QLQ-BM22 quality of life evaluation and pain outcome in patients with bone metastases from breast cancer treated with zoledronic acid
Dah-Cherng Yeh, Dar-Ren Chen, Tsu-Yi Chao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 29, 2020
A Phase Ib Study of Alpelisib or Buparlisib Combined with Tamoxifen Plus Goserelin in Premenopausal Women with HR-Positive HER2-Negative Advanced Breast Cancer
Yen-Shen Lu, Keun Seok Lee, Tsu-Yi Chao, et al.
JAMA Oncology
|
October 25, 2019
Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial
Zhimin Shao, Da Pang, Hongjian Yang, et al.
Nature Communications
|
March 9, 2024
Neoadjuvant-adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trial
Liang Huang, Da Pang, Hongjian Yang, et al.
Cancer Research
|
June 28, 2014
Definition of PKC-α, CDK6, and MET as therapeutic targets in triple-negative breast cancer
Yi-Hsin Hsu, Jun Yao, Li-Chuan Chan, et al.
Molecular Cell
|
July 24, 2025
Phosphorylation of EZH2 by AMPK Suppresses PRC2 Methyltransferase Activity and Oncogenic Function
Lixin Wan, Kexin Xu, Yongkun Wei, et al.
Molecular Cell
|
August 14, 2025
WITHDRAWN: Phosphorylation of EZH2 by AMPK Suppresses PRC2 Methyltransferase Activity and Oncogenic Function
Lixin Wan, Kexin Xu, Yongkun Wei, et al.
Molecular Cell
|
January 21, 2018
Phosphorylation of EZH2 by AMPK Suppresses PRC2 Methyltransferase Activity and Oncogenic Function
Lixin Wan, Kexin Xu, Yongkun Wei, et al.
JAMA Oncology
|
December 21, 2023
Whole-Brain Radiotherapy Alone vs Preceded by Bevacizumab, Etoposide, and Cisplatin for Untreated Brain Metastases From Breast Cancer: A Randomized Clinical Trial
Tom Wei-Wu Chen, Ming-Shen Dai, Ling-Ming Tseng, et al.
Nature Medicine
|
January 19, 2016
Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors
Yi Du, Hirohito Yamaguchi, Yongkun Wei, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 74) with videos related to
Sort By:
Page
of 8
In Vivo (Athens, Greece)
|
September 6, 2014
EORTC QLQ-BM22 quality of life evaluation and pain outcome in patients with bone metastases from breast cancer treated with zoledronic acid
Dah-Cherng Yeh, Dar-Ren Chen, Tsu-Yi Chao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 29, 2020
A Phase Ib Study of Alpelisib or Buparlisib Combined with Tamoxifen Plus Goserelin in Premenopausal Women with HR-Positive HER2-Negative Advanced Breast Cancer
Yen-Shen Lu, Keun Seok Lee, Tsu-Yi Chao, et al.
JAMA Oncology
|
October 25, 2019
Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial
Zhimin Shao, Da Pang, Hongjian Yang, et al.
Nature Communications
|
March 9, 2024
Neoadjuvant-adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trial
Liang Huang, Da Pang, Hongjian Yang, et al.
Cancer Research
|
June 28, 2014
Definition of PKC-α, CDK6, and MET as therapeutic targets in triple-negative breast cancer
Yi-Hsin Hsu, Jun Yao, Li-Chuan Chan, et al.
Molecular Cell
|
July 24, 2025
Phosphorylation of EZH2 by AMPK Suppresses PRC2 Methyltransferase Activity and Oncogenic Function
Lixin Wan, Kexin Xu, Yongkun Wei, et al.
Molecular Cell
|
August 14, 2025
WITHDRAWN: Phosphorylation of EZH2 by AMPK Suppresses PRC2 Methyltransferase Activity and Oncogenic Function
Lixin Wan, Kexin Xu, Yongkun Wei, et al.
Molecular Cell
|
January 21, 2018
Phosphorylation of EZH2 by AMPK Suppresses PRC2 Methyltransferase Activity and Oncogenic Function
Lixin Wan, Kexin Xu, Yongkun Wei, et al.
JAMA Oncology
|
December 21, 2023
Whole-Brain Radiotherapy Alone vs Preceded by Bevacizumab, Etoposide, and Cisplatin for Untreated Brain Metastases From Breast Cancer: A Randomized Clinical Trial
Tom Wei-Wu Chen, Ming-Shen Dai, Ling-Ming Tseng, et al.
Nature Medicine
|
January 19, 2016
Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors
Yi Du, Hirohito Yamaguchi, Yongkun Wei, et al.
Page
of 8